Treatment with low-dose cytokines reduces oxidative-mediated injury in perilesional keratinocytes from vitiligo skin. Issue 2 (August 2015)

• Record Type: Journal Article
• Authors: Barygina, Victoria; Becatti, Matteo; Lotti, Torello; Moretti, Silvia; Taddei, Niccolò; Fiorillo, Claudia
• Is Part Of: Journal of dermatological science. Volume 79:Issue 2(2015:Aug.)
• Page Start: 163
• Page End: 170
• Publication Date: 2015-08
• Subjects: Dermatology -- Periodicals; Skin Diseases -- Periodicals; Dermatologie -- Périodiques; 616.5005
• DOI: 10.1016/j.jdermsci.2015.05.003
• Languages: English
• ISSNs: 0923-1811

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Primary perilesional keratinocytes (PLK) obtained from vitiligo patients were used.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">PLK were treated with low-dose 10 fg/ml IL-4, IL-10, bFGF and β-endorphin for 48 h.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">IL-4, IL-10, bFGF and β-endorphin were prepared by sequential-kinetic-activation.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Treatment reduced extra- and intracellular ROS production, increased viability in PLK.</p> </list-item> <list-item id="lsti0025"> <label></label> <p id="par0025">Low-dose IL-4, IL-10, bFGF and β-endorphin represent a therapeutic tool for vitiligo.</p> </list-item> </list> </p> </sec> </abstract>